Slide 1: DMX-200 for FSGS
@w Dimerix ' (ASX:DXB) DMX-200 for FSGS ~ Non-confidential | % July 2024 Developing new therapies to treat inflammatory causes of kidney and respiratory disease with unmet clinical needs
Slide 2: Significantly de-risked, late-stage development program
Significantly de-risked, late-stage development program rie Strong safety profile— no Encouraging efficacyin Completed all —, material adverse events in Phase 2 and successful safety for FDA and EMA Phase 1, 2 and3 interim analysis in Phase 3 a Tl ay il Completed commercial Clear development and Orp
Slide 3: Board of Directors
Mark Diamond Nina Webster Hugh Alsop Sonia Poli Clinton Snow BSc, MBA PhD, MBA, M.IP.Law BSc (Hons), MBA PhD BEng (Hons), BCom Non-Executive Chairman CEO & Managing Director Non-Executive Director Non-Executive Director Non-Executive Director Antisense, Faulding (Pfizer) Wyeth (Pfizer), Acrux, Immur
Slide 4: Management team
Nina Webster Hamish George David Fuller Robert Shepherd Bronwyn Pollock PhD, MBA, M.IP.Law BCom, CA, GIA(Cert) B.Pharm (Hons), MBBS PhD MBA BSc (Hons), MBA CEO & Managing Director CFO & Company Secretary CMO CCO VP, Product Development Wyeth (Pfizer), Acrux, Immuron Bio101, Pitcher Partners Race Onc
Slide 5: Scientific advisory board
Professor Hiddo Heerspink Dr Muh Geot Wong Professor Alessia Fornoni Professor Jonathan Barratt Associate Professor Lesley Inker PhD MBBS, PhD, FRCP MD, PhD, FASN MD, PhD, FRCP MD, MS, FRCPC Chairman Member Member Member Member
Slide 6: Development pipeline
Development pipeline Program Indication Core focus Focal Segmental Glomerular Sclerosis (FSGS) DMX-200 Diabetic Kidney Disease Preclinical Phase 1 DMX-700 Chronic Obstructive Pulmonary Disease (COPD) DMX-xxx Undisclosed (multiple)
Slide 7: What is the patient journey of Focal Segmental Glomerulosclerosis (FSGS)?
What is the patient journey of Focal Segmental Glomerulosclerosis (FSGS)? * Focal segmental glomerulosclerosis (FSGS) is one of the most common forms of acquired glomerular disease leading to end stage kidney disease (ESKD) + FSGS makes up approximately 10% of all kidney diseases! + Onaverage FSGS p
Slide 8: Key mechanisms that cause sclerotic kidney disease
3 key mechanisms that cause sclerotic kidney disease AT1R — blocked by angiotensin receptor blocker (ARB) ov Less filtering cells hyperfiltration and CCR2-—CCR2 is the receptor for Lo MCP-1; DMX-200 inhibits CCR2 to block attraction of inflammatory cells into the kidneys? 1 Hyperfiltration of and hy
Slide 9: Proposed non-clinical safety package suitability for NDA confirmed with FDA
• • • Proposed non-clinical safety package suitability for NDA confirmed with FDA
Slide 10: DMX-200 is a strong product candidate
DMX-200 is a strong product candidate A CCR2 inhibitor working synergistically alongside the current standard of care (ATIR blocker): G protein-coupled receptor (GPCR) New Chemical Entity status, 2 x 120mg capsule daily Consistently safe and well 4 clinical studies completed with orphan exclusivity
Slide 11: DMX-200 met Phase 2a clinical study endpoints
DMX-200 met Phase 2a clinical study endpoints Clinically meaningful outcomes for patients EFFICACY * 86% of patien demonstrated redu proteinuria on DMX-200. versus pl O * 29% of patients demonstrated >40% duction in proteinuria SAFETY No safety concerns — reduced development risk * DMX-200 compares
Slide 12: uMCR normalised to baseline v time
uMCR normalised to baseline v time N=7, GeoMean 50% 1.5 uMCR normalised 0% 1.0 -50% 0.5 On placebo On active 0.0 0 5 10 15 Time (weeks) • ▪
Slide 13: ACTION3 Global phase 3 clinical trial
Oo ACTICIN3 Global phase 3 clinical trial FSGS CLINICAL STUDY A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB eeks \ 23 Q gs i r ay ARB + placebo P hi 5 a sects recrultert then 3 3 P Part 1: First interim! Part 2:
Slide 14: ACTION3 Current and planned clinical sites
O ACTING Current and planned clinical sites FSGS CLINICAL STUDY A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB Recruitment planned at 170+ sites in: ¢ Australia, New Zealand * Taiwan, Hong Kong, Malaysia, Thailan
Slide 15: Global partnering availability
Global partnering availability [1s Available m ADVANZ PHARMA’ @ (%taiba @ Dimerix al
Slide 16: Low competitive landscape in FSGS
Low competitive landscape in FSGS DMX-200 is the leading therapy in phase 3 development for FSGS Phase 1 Phase 2 Phase 3 Company DMX-200 (ATIR&CCR2 VX-147 (APOL') Vertex Pharmaceuticals BI-764198 (TRPC6) Boehringer Ingelheim Atrasentan (ETAR) Chinook/Novartis River3Renal Sources: Company Documents,
Slide 17: Strong exclusivity and intellectual property
Strong exclusivity and intellectual property /10+ years Orphan 2 042 2 032 exclusivity in Method of Use Method of Use any territori Global application Granted any CCR2 antagonist with any CCR2 inhibitor with any endothelin A receptor any ARB for any kidney for any disease disease NCE status exclusiv